AllianceRx Walgreens Prime is a specialty and home delivery pharmacy that strives to provide exceptional care throughout a patient’s treatment journey with the medications they need every day.
Formed in 2017 through a collaboration between Walgreens and Prime Therapeutics, the company offers tools and resources for patients, providers and health plans to deliver the optimal health outcomes.
A new patented process for delivering specialty medicine will assure AllianceRx Walgreens Prime patients receive their medicine delivered at the correct temperature.
AllianceRx Walgreens Prime will exclusively use the patent – held by parent company Walgreens – to help increase patient safety, improve patient outcomes and reduce waste. It is the only specialty pharmacy to offer a patented cold-chain shipment packaging process.
In specialty pharmacy, cold-chain distribution refers to the process of shipping medicines that require refrigerated storage. Maintaining the right temperatures is critical to ensuring the efficacy of specialty medications, including costly biologics and injectables, which have special storage or temperature requirements. One of the new URAC specialty pharmacy accreditation standards is PHARM-OP 7 Cold Chain Distribution.
According to state and local economic development sources, AllianceRX Walgreens plans to invest $6.5 million to build out 93,250 square feet of new space in Dallas. The company is creating new jobs at this facility. The company plans to occupy the new space at 8600 Harry Hines Blvd in Dallas, on or about September 1, 2020.
Takeaway: With nearly 3,000 employees and several locations across the U.S., AllianceRx Walgreens Prime serves millions of patients offering tools and resources to provide care